In 58 patients diagnosed with acute adenoviral conjunctivitis, OKG-0301 was safe and demonstrated an effective, dose-dependent anti-viral response.
San Diego, California and Melbourne, Australia--(Newsfile Corp. - April 29, 2021) - Okogen, a clinical-stage specialty ophthalmic biotechnology company announced the interim analysis results from RUBY, the company’s Phase 2, double-masked, placebo-controlled clinical trial evaluating the safety and efficacy of OKG-0301 in patients with acute adenoviral conjunctivitis. In 58 patients diagnosed with acute adenoviral conjunctivitis, OKG-0301 was safe and demonstrated an effective, dose-dependent anti-viral response. This data will be presented by Professor Stephanie Watson (Principal Investigator of the RUBY Trial) in greater detail at the ARVO virtual annual meeting, May 1-7, 2021.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- In 58 patients diagnosed with acute adenoviral conjunctivitis, OKG-0301 was safe and demonstrated an effective, dose-dependent anti-viral response.
- Data to be presented at Association for Research in Vision and Ophthalmology (ARVO) annual conference being held May 1-7, 2021
- Building off this data, the company has put forth its planned clinical development steps to the US FDA, outlining a phase 3 program to begin in 2022.
Click image above to view full announcement.
About Okogen
Okogen is a clinical-stage, specialty biotechnology company focused on developing therapeutics to help patients with ocular diseases. The company’s lead development candidate, OKG-0502, is a fixed dose combination of a broad-spectrum antiviral (OKG-0301) that functions intracellularly to inhibit viral replication and an ocular decongestant that addresses the associated signs and symptoms of adenoviral conjunctivitis. These mechanisms of action are further expected to provide clinical benefit in addressing adenoviral infections of the eye as well as other classes of viruses that are active in the ocular space, including herpes simplex virus, varicella-zoster virus, and more.
For more information about Okogen, visit www.okogen.com. To learn more about the RUBY trial, visit www.rubytrial.com.au or clinicaltrials.gov (NCT03856645).
Contacts:
Brian M. Strem, Ph.D.
info@okogen.com
Source: Okogen
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/82293
